Literature DB >> 3971481

Comparative cytotoxicities of various morpholinyl anthracyclines.

D G Streeter, D L Taylor, E M Acton, J H Peters.   

Abstract

A series of quinone- and sugar-modified analogs of adriamycin have been tested for growth inhibition of adriamycin-sensitive (P388/S) and -resistant (P388/ADR) sublines of P388 murine leukemia cells in vitro. P388/ADR is less resistant to analogs of adriamycin containing either a 3'-deamino-3'-(4"-morpholinyl) group, MRA; or a -(3"-cyano-4"-morpholinyl) group, MRA-CN, than to adriamycin. However, MRA-CN was the most potent growth inhibitor of either subline. This potency is reduced by either modification of the quinone unit with a 5-imino substituent or restriction of the cyano-morpholinyl ring by an oxygen bridge to the daunosamine sugar. The calcium antagonist verapamil substantially increases the cytotoxicity of adriamycin to P388/ADR but has no appreciable effect on the cytotoxicity of either MRA or MRA-CN. The results suggest that increased uptake and retention by both MRA and MRA-CN may contribute to their increased cytotoxicity, but that the intense potency of the cyano-morpholinyl analogs must be due to other unique properties of these compounds.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3971481     DOI: 10.1007/bf00434357

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  14 in total

1.  Diminished superoxide anion generation by reduced 5-iminodaunorubicin relative to daunorubicin and the relationship to cardiotoxicity of the anthracycline antitumor agents.

Authors:  J W Lown; H H Chen; J A Plambeck; E M Acton
Journal:  Biochem Pharmacol       Date:  1979-09-01       Impact factor: 5.858

2.  Uptake and retention of adriamycin and daunorubicin by sensitive and anthracycline-resistant sublines of P388 leukemia.

Authors:  M Inaba; R K Johnson
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

3.  Pharmacological studies of 3'-(4-morpholinyl)-3'-deaminodaunorubicin in human colon carcinoma cells in vitro.

Authors:  J B Johnston; R I Glazer
Journal:  Cancer Res       Date:  1983-03       Impact factor: 12.701

4.  Mitochondrial NADH dehydrogenase-catalyzed oxygen radical production by adriamycin, and the relative inactivity of 5-iminodaunorubicin.

Authors:  K J Davies; J H Doroshow; P Hochstein
Journal:  FEBS Lett       Date:  1983-03-07       Impact factor: 4.124

5.  Differences in daunomycin retention in sensitive and resistant P388 leukemic cells as determined by digitized video fluorescence microscopy.

Authors:  S Yanovich; R N Taub
Journal:  Cancer Res       Date:  1983-09       Impact factor: 12.701

6.  Intensely potent morpholinyl anthracyclines.

Authors:  E M Acton; G L Tong; C W Mosher; R L Wolgemuth
Journal:  J Med Chem       Date:  1984-05       Impact factor: 7.446

7.  Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia.

Authors:  M Inaba; H Kobayashi; Y Sakurai; R K Johnson
Journal:  Cancer Res       Date:  1979-06       Impact factor: 12.701

8.  Effects of 5-iminodaunorubicin on nucleoli of rats.

Authors:  J H Peters; M J Evans; R A Jensen; E M Acton
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

9.  Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1981-05       Impact factor: 12.701

10.  Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

View more
  9 in total

1.  Neurotoxicity and dermatotoxicity of cyanomorpholinyl adriamycin.

Authors:  S C Cramer; R H Rhodes; E M Acton; Z A Tökés
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Morpholinylanthracyclines: cytotoxicity and antitumor activity of differently modified derivatives.

Authors:  M Ripamonti; L Capolongo; G Melegaro; C Gornati; A Bargiotti; M Caruso; M Grandi; A Suarato
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 3.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

4.  The role of methoxymorpholino anthracycline and cyanomorpholino anthracycline in a sensitive small-cell lung-cancer cell line and its multidrug-resistant but P-glycoprotein-negative and cisplatin-resistant counterparts.

Authors:  W T van der Graaf; N H Mulder; C Meijer; E G de Vries
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

5.  Effects of the methoxymorpholino derivative of doxorubicin and its bioactivated form versus doxorubicin on human leukemia and lymphoma cell lines and normal bone marrow.

Authors:  J S Kühl; G E Durán; N J Chao; B I Sikic
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Uptake and retention of morpholinyl anthracyclines by adriamycin-sensitive and -resistant P388 cells.

Authors:  D G Streeter; J S Johl; G R Gordon; J H Peters
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin.

Authors:  A Nagy; P Armatis; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

8.  Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines.

Authors:  H M Coley; W B Amos; P R Twentyman; P Workman
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

9.  Metabolic conversion of methoxymorpholinyl doxorubicin: from a DNA strand breaker to a DNA cross-linker.

Authors:  D H Lau; G E Duran; A D Lewis; B I Sikic
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.